TLSA
TLSA clinical trials: Tiziana Life Sciences Ltd
Every trial on ClinicalTrials.gov where Tiziana Life Sciences Ltd is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 15
- Trials linked
- 14
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
TLSA on the catalyst calendar · TLSA registry changes
- Primary completion Sep 17, 2026ActualPhase 2NCT06292923A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsTiziana Life Sciences LTD · Secondary Progressive Multiple SclerosisCompletedTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 2NCT07688239The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal ForalumabTiziana Life Sciences LTD · ALS (Amyotrophic Lateral Sclerosis)Enrolling by invitationTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2027Sponsor estimatePhase 2NCT06868628A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)Tiziana Life Sciences LTD · Multiple System AtrophyRecruitingTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2026Sponsor estimatePhase 2NCT06890923Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple SclerosisTiziana Life Sciences LTD · Non-Active Secondary Progressive Multiple SclerosisRecruitingTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06802328Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS PatientsTiziana Life Sciences LTD · Non-Active Secondary Progressive Multiple SclerosisAvailableTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 23, 2019ActualPhase 1NCT06879067Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human VolunteersTiziana Life Sciences LTD · SafetyCompletedTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2024Sponsor estimatePhase 2NCT05651269Milciclib in Combination With Gemcitabine in Advanced NSCLCTiziana Life Sciences LTD · NSCLCUnknown statusTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2023Sponsor estimatePhase 1NCT05028946A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's DiseaseTiziana Life Sciences LTD · Crohn's DiseaseWithdrawnTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2022Sponsor estimatePhase 2NCT04983446In-patient COVID-19 Study of Intranasal ForalumabTiziana Life Sciences LTD · Covid19WithdrawnTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2022Sponsor estimatePhase 1NCT05029609Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MSTiziana Life Sciences LTD · Primary Progressive Multiple SclerosisWithdrawnTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 16, 2019ActualPhase 2NCT03109886Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular CarcinomaTiziana Life Sciences LTD · Hepatocellular CarcinomaCompletedTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2018Sponsor estimatePhase 2NCT03291249Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DMTiziana Life Sciences LTD · NASH - Nonalcoholic SteatohepatitisWithdrawnTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2017ActualPhase 2NCT01301391Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of ChemotherapyTiziana Life Sciences LTD · Malignant ThymomaTerminatedTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2017ActualPhase 2NCT01011439Phase II Study Of Oral PHA-848125AC In Patients With Thymic CarcinomaTiziana Life Sciences LTD · Thymic CarcinomaTerminatedTLSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2026Sponsor estimatePhase 2NCT06489548Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's DiseaseBrigham and Women's Hospital · DementiaRecruitingTLSACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 15 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner